A synthetic lethal interaction between glutathione synthesis and mitochondrial reactive oxygen species provides a tumor-specific vulnerability dependent on STAT3

Molecular and Cellular Biology

Volumn 35, Issue 21, 2015, Pages 3646-3656

  Garama, Daniel J ^b,c   Harris, Tiffany J ^b,c   White, Christine L ^b,c   Rossello, Fernando J ^c   Abdul Hay, Maher ^a   Gough, Daniel J ^a,b,c   Levy, David E ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; GLUTATHIONE DISULFIDE; MITOCHONDRIAL PROTEIN; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN;

ADULT; ANIMAL CELL; ARTICLE; BLADDER CANCER CELL LINE; BLADDER CARCINOMA; BONE MARROW CELL; CARCINOGENESIS; CELL DEATH; CELL TRANSFORMATION; DNA DAMAGE; EMBRYO; ENZYME INHIBITION; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MITOCHONDRIAL RESPIRATION; MOLECULAR INTERACTION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEPLETION; REGULATORY MECHANISM; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; GENETICS; METABOLISM; MITOCHONDRION; NEOPLASM; ONCOGENE RAS; PATHOLOGY;

ANIMALS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; GAMMA-GLUTAMYLTRANSFERASE; GENES, RAS; GLUTATHIONE; HUMANS; MICE; MITOCHONDRIA; NEOPLASMS; REACTIVE OXYGEN SPECIES; STAT3 TRANSCRIPTION FACTOR;

EID: 84944610909     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00541-15     Document Type: Article

References (50)

1. Levy DE, Lee CK. 2002. What does Stat3 do? J Clin Investig 109:1143-1148. http://dx.doi.org/10.1172/JCI0215650.
2. Yu H, Lee H, Herrmann A, Buettner R, Jove R. 2014. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 14:736-746. http://dx.doi.org/10.1038/nrc3818.
3. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE, Jr. 1999. Stat3 as an oncogene. Cell 98:295-303. http://dx.doi.org/10.1016/S0092-8674(00)81959-5.
4. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE. 2005. New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell Cycle 4:1131-1133. http://dx.doi.org/10.4161/cc.4.9.1985.
5. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE. 2009. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 324:1713-1716. http://dx.doi.org/10.1126/science.1171721.
6. Zhang Q, Raje V, Yakovlev VA, Yacoub A, Szczepanek K, Meier J, Derecka M, Chen Q, Hu Y, Sisler J, Hamed H, Lesnefsky EJ, Valerie K, Dent P, Larner AC. 2013. Mitochondrial localized Stat3 promotes breast cancer growth via phosphorylation of serine 727. J Biol Chem 288:31280-31288. http://dx.doi.org/10.1074/jbc.M113.505057.
7. Gough DJ, Marie IJ, Lobry C, Aifantis I, Levy DE. 2014. STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation. Blood 124:2252-2261. http://dx.doi.org/10.1182/blood-2013-02-484196.
8. Gough DJ, Sehgal PB, Levy DE. 2012. Nongenomic functions of STAT3, p 91-98. In Decker T, Müller M (ed), Jak-Stat signaling: from basics to disease. Springer-Verlag Gmbh, Vienna, Germany.
9. Yue P, Turkson J. 2009. Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 18:45-56. http://dx.doi.org/10.1517/13543780802565791.
10. Wake MS, Watson CJ. 2015. STAT3 the oncogene-still eluding therapy? FEBS J 282:2600-2611. http://dx.doi.org/10.1111/febs.13285.
11. Warburg O. 1956. On the origin of cancer cells. Science 123:309-314. http://dx.doi.org/10.1126/science.123.3191.309.
12. Lunt SY, Vander Heiden MG. 2011. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 27: 441-464. http://dx.doi.org/10.1146/annurev-cellbio-092910-154237.
13. Calabrese C, Iommarini L, Kurelac I, Calvaruso MA, Capristo M, Lollini PL, Nanni P, Bergamini C, Nicoletti G, Giovanni CD, Ghelli A, Giorgio V, Caratozzolo MF, Marzano F, Manzari C, Betts CM, Carelli V, Ceccarelli C, Attimonelli M, Romeo G, Fato R, Rugolo M, Tullo A, Gasparre G, Porcelli AM. 2013. Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells. Cancer Metab 1:11. http://dx.doi.org/10.1186/2049-3002-1-11.
14. Demaria M, Giorgi C, Lebiedzinska M, Esposito G, D'Angeli L, Bartoli A, Gough DJ, Turkson J, Levy DE, Watson CJ, Wieckowski MR, Provero P, Pinton P, Poli V. 2010. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging 2:823-842.
15. Downward J. 2003. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11-22. http://dx.doi.org/10.1038/nrc969.
16. Schumacher T, Bunse L, Wick W, Platten M. 2014. Mutant IDH1: an immunotherapeutic target in tumors. Oncoimmunology 3:e974392. http://dx.doi.org/10.4161/2162402X.2014.974392.
17. Chaturvedi A, Araujo Cruz MM, Jyotsana N, Sharma A, Yun H, Gorlich K, Wichmann M, Schwarzer A, Preller M, Thol F, Meyer J, Haemmerle R, Struys EA, Jansen EE, Modlich U, Li Z, Sly LM, Geffers R, Lindner R, Manstein DJ, Lehmann U, Krauter J, Ganser A, Heuser M. 2013. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 122:2877-2887. http://dx.doi.org/10.1182/blood-2013-03-491571.
18. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15: 3243-3248. http://dx.doi.org/10.1101/gad.943001.
19. Raz R, Lee CK, Cannizzaro LA, d' Eustachio P, Levy DE. 1999. Essential role of STAT3 for embryonic stem cell pluripotency. Proc Natl Acad Sci U S A 96:2846-2851. http://dx.doi.org/10.1073/pnas.96.6.2846.
20. Meister A. 1974. The gamma-glutamyl cycle. Diseases associated with specific enzyme deficiencies. Ann Intern Med 81:247-253.
21. Soga T, Baran R, Suematsu M, Ueno Y, Ikeda S, Sakurakawa T, Kakazu Y, Ishikawa T, Robert M, Nishioka T, Tomita M. 2006. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J Biol Chem 281:16768-16776. http://dx.doi.org/10.1074/jbc.M601876200.
22. Glasauer A, Sena LA, Diebold LP, Mazar AP, Chandel NS. 2014. Targeting SOD1 reduces experimental non-small-cell lung cancer. J Clin Investig 124:117-128. http://dx.doi.org/10.1172/JCI71714.
23. Zhang X, Zhang J, Wei H, Tian Z. 2007. STAT3-decoy oligodeoxynucleotide inhibits the growth of human lung cancer via down-regulating its target genes. Oncol Rep 17:1377-1382.
24. Braun BS, Shannon K. 2008. Targeting Ras in myeloid leukemias. Clin Cancer Res 14:2249-2252. http://dx.doi.org/10.1158/1078-0432.CCR-07-1005.
25. Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, Johnson L, Akashi K, Tuveson DA, Jacks T, Gilliland DG. 2004. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Investig 113:528-538. http://dx.doi.org/10.1172/JCI20476.
26. Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegue E, Shannon K, Braun BS. 2009. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol 7:e59. http://dx.doi.org/10.1371/journal.pbio.1000059.
27. Zhang J, Liu Y, Beard C, Tuveson DA, Jaenisch R, Jacks TE, Lodish HF. 2007. Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways. Blood 109:5238-5241. http://dx.doi.org/10.1182/blood-2006-09-047050.
28. Giordano G, White CC, McConnachie LA, Fernandez C, Kavanagh TJ, Costa LG. 2006. Neurotoxicity of domoic acid in cerebellar granule neurons in a genetic model of glutathione deficiency. Mol Pharmacol 70: 2116-2126. http://dx.doi.org/10.1124/mol.106.027748.
29. Griffith OW. 1982. Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J Biol Chem 257:13704-13712.
30. Wegrzyn J, Potla R, Chwae YJ, Sepuri NB, Zhang Q, Koeck T, Derecka M, Szczepanek K, Szelag M, Gornicka A, Moh A, Moghaddas S, Chen Q, Bobbili S, Cichy J, Dulak J, Baker DP, Wolfman A, Stuehr D, Hassan MO, Fu XY, Avadhani N, Drake JI, Fawcett P, Lesnefsky EJ, Larner AC. 2009. Function of mitochondrial Stat3 in cellular respiration. Science 323: 793-797. http://dx.doi.org/10.1126/science.1164551.
31. Shen Y, Schlessinger K, Zhu X, Meffre E, Quimby F, Levy DE, Darnell JE, Jr. 2004. Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. Mol Cell Biol 24:407-419. http://dx.doi.org/10.1128/MCB.24.1.407-419.2004.
32. Kumar A, Bachhawat AK. 2010. A futile cycle, formed between two ATP-dependant gamma-glutamyl cycle enzymes, gamma-glutamyl cysteine synthetase and 5-oxoprolinase: the cause of cellular ATP depletion in nephrotic cystinosis? J Biosci 35:21-25. http://dx.doi.org/10.1007/s12038-010-0004-8.
33. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR, Chandel NS. 2010. Mitochondrial metabolism and ROS generation are essential for Krasmediated tumorigenicity. Proc Natl Acad Sci U S A 107:8788-8793. http://dx.doi.org/10.1073/pnas.1003428107.
34. Murphy MP. 2009. How mitochondria produce reactive oxygen species. Biochem J 417:1-13. http://dx.doi.org/10.1042/BJ20081386.
35. Dello SA, Neis EP, de Jong MC, van Eijk HM, Kicken CH, Olde Damink SW, Dejong CH. 2013. Systematic review of ophthalmate as a novel biomarker of hepatic glutathione depletion. Clin Nutr 32:325-330. http://dx.doi.org/10.1016/j.clnu.2012.10.008.
36. Hussain SP, Hofseth LJ, Harris CC. 2003. Radical causes of cancer. Nat Rev Cancer 3:276-285. http://dx.doi.org/10.1038/nrc1046.
37. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ. 1997. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275:1649-1652. http://dx.doi.org/10.1126/science.275.5306.1649.
38. Irani K, Goldschmidt-Clermont PJ. 1998. Ras, superoxide and signal transduction. Biochem Pharmacol 55:1339-1346. http://dx.doi.org/10.1016/S0006-2952(97)00616-3.
39. Liou JS, Chen CY, Chen JS, Faller DV. 2000. Oncogenic ras mediates apoptosis in response to protein kinase C inhibition through the generation of reactive oxygen species. J Biol Chem 275:39001-39011. http://dx.doi.org/10.1074/jbc.M007154200.
40. Chuang JI, Chang TY, Liu HS. 2003. Glutathione depletion-induced apoptosis of Ha-ras-transformed NIH3T3 cells can be prevented by melatonin. Oncogene 22:1349-1357. http://dx.doi.org/10.1038/sj.onc.1206289.
41. Roy S, Maity P. 2007. Modulation of metastatic potential of B16F10 melanoma cells by acivicin: synergistic action of glutaminase and potentiation of cisplatin cytotoxicity. Asian Pac J Cancer Prev 8:301-306.
42. Maroun JA, Stewart DJ, Verma S, Evans WK, Eisenhauer E. 1990. Phase I study of acivicin and cisplatin in non-small-cell lung cancer. A National Cancer Institute of Canada study. Am J Clin Oncol 13:401-404.
43. Bonomi P, Finkelstein D, Chang A. 1994. Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 17:215-217.
44. Taylor SA, Crowley J, Pollock TW, Eyre HJ, Jaeckle C, Hynes HE, Stephens RL. 1991. Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: a Southwest Oncology Group trial. J Clin Oncol 9:1476-1479.
45. Powell BL, Craig JB, Capizzi RL, Richards F, Jr. 1988. Phase I-II trial of acivicin in adult acute leukemia. Investig New Drugs 6:41-44.
46. Falkson G, Cnaan A, Simson IW, Dayal Y, Falkson H, Smith TJ, Haller DG. 1990. A randomized phase II study of acivicin and 4'deoxydoxorubicin in patients with hepatocellular carcinoma in an Eastern Cooperative Oncology Group study. Am J Clin Oncol 13:510-515. http://dx.doi.org/10.1097/00000421-199012000-00012.
47. Earhart RH, Khandekar JD, Faraggi D, Schinella RA, Davis TE. 1989. Phase II trial of continuous drug infusions in advanced ovarian carcinoma: acivicin versus vinblastine. Investig New Drugs 7:255-260.
48. Longnecker DS, Curphey TJ. 1975. Adenocarcinoma of the pancreas in azaserine-treated rats. Cancer Res 35:2249-2258.
49. Sava G, Giraldi T, Baldini L. 1982. Antitumor activity of N-diazoacetyl derivatives of glycine and phenylalanine against P388 leukemia and B16 melanoma in mice. Cancer Treat Rep 66:179-181.
50. Kreuzer J, Bach NC, Forler D, Sieber SA. 2014. Target discovery of acivicin in cancer cells elucidates its mechanism of growth inhibition. Chem Sci 6:237-245. http://dx.doi.org/10.1039/c4sc02339k.